That changed when the pipeline shifted. Cell and gene therapies, personalized medicine, and shrinking batch sizes have moved clinical logistics from batch-push toward patient-level pull. In that model, there is no batch to average across. Every shipment is its own compliance and logistics event — and when the final leg fails, there is no next batch to recover with.
In a batch-push model, last-mile failures are quality events. A temperature excursion on one unit of a commercial drug shipment triggers a quality investigation — not a program loss. The batch buffer absorbs the failure, documentation is generated, and the program continues.
In a patient-level pull model, that buffer doesn’t exist. A cell therapy collected from a specific patient, a clinical trial sample tied to a single investigator visit, a biological intermediate that cannot be reacquired — these aren’t units in a batch. They’re singular. When the final leg fails for any of these materials, the loss is total: product, data, timeline, and in some cases, the research chain itself.
The last mile hasn’t changed operationally. What changed is what a last-mile failure now costs.
Most cold chain logistics providers own the middle of the chain well. Temperature-controlled depots, validated storage, monitoring platforms — these are now standard infrastructure at the major providers. The last mile is where that infrastructure ends and the handoff happens.
When the final leg is sub-contracted, it goes to a party who often knows nothing about the shipment’s origin, compliance history, temperature requirements, or documentation obligations. The GDP chain of custody that was maintained from origin through depot terminates at the handoff — and what the last-mile carrier produces in its place is a delivery confirmation, not a compliance record.
For clinical trial materials and investigational products, a documentation gap at last-mile handoff creates a regulatory exposure that surfaces at filing — often months after the shipment moved. The temperature record may be complete. The chain-of-custody record is not. Both must be unbroken for the data to hold.
If your cold chain provider hands off the final leg to a sub-contracted carrier, the GDP chain of custody ends at that handoff — regardless of what the temperature record shows. Eagle owns last-mile delivery from Logan with white-glove drivers, owned temperature-controlled vehicles, and no relay through parties who weren’t in the compliance chain.
The final leg carries more variables than any other segment of the cold chain: more stops, more handling events, more exposure to ambient conditions during loading and unloading, and more distance from the compliance oversight that governed earlier legs. It’s also the least standardized — a depot-to-hospital delivery and a depot-to-investigator-site delivery don’t look the same operationally, and a sub-contracted carrier treats both as standard freight.
Temperature excursions in last mile delivery are disproportionately represented in pharmaceutical cold chain failures — not because the final leg is longer, but because it’s the leg most likely to be handled by a party operating outside the compliance framework that governed everything before it. The excursion happens. The accountability is diffuse. By the time the deviation is identified, the shipment is at its destination and the recovery window has closed.
Proximity to the air freight hub shortens the ground transit time and the exposure window. An operator who owns the vehicles, the drivers, and the compliance documentation owns the outcome when something goes wrong. A sub-contracted carrier owns the delivery receipt.
Eagle manages the full import-to-last-mile chain under one operator, less than 2 miles from Logan. The last mile is not handed off to a party who wasn’t present for the rest of the chain. Eagle’s white-glove drivers know what they’re carrying, why the temperature profile matters, and what the documentation requirements are at delivery — because they’re operating under the same GDP-aligned quality framework as every other leg of the shipment.
Owned temperature-controlled vehicles and vans handle first and last mile delivery across the Boston region, with nightly line-haul to JFK and Newark for programs requiring broader distribution. The chain-of-custody record is continuous from Logan arrival through final receipt — no relay through generic depots, no sub-handoffs to parties operating outside the pharmaceutical compliance framework, no visibility gaps at the leg where gap risk is highest.
For programs delivering to hospital networks, clinical sites, and research facilities across New England, cGMP-aligned warehousing at Eagle’s Chelsea facility serves as the regional depot — less than 2 miles from Logan, with validated cold storage at every temperature range the program requires, and direct connection to owned last-mile delivery assets.
When something goes wrong at the last mile, Eagle responds from the operator’s position — not the observer’s. Rescue repack, same-day re-delivery, and exception management are executed by the party who has been accountable for the shipment since Logan. Not called in after the fact.
The final leg combines the highest number of handling events, the most variable infrastructure, and the greatest disconnect from the compliance oversight that governed earlier legs. Sub-contracted last-mile carriers handle pharmaceutical cargo alongside general freight, without the GDP-compliant SOPs, trained personnel, or chain-of-custody documentation the material requires. Excursions happen in the last mile at a higher rate than in air or ocean segments — not because the leg is longer, but because the compliance framework breaks down at the handoff.
It requires that every handling event, temperature reading, and change of custody from origin through final receipt be documented under the same quality management system — continuously, without gaps. That means the last-mile carrier isn’t generating a separate, independently formatted delivery record that gets appended to the chain. It means one documentation framework, one set of SOPs, one operator accountable for the record from first touchpoint through delivery. That’s only possible when the last-mile carrier is the same operator, not a sub-contracted party producing its own records in its own format.
Proximity reduces ground transit time, which directly reduces the temperature exposure window in the final leg. But the more significant factor is that proximity allows Eagle to own both the depot and the last-mile delivery under one operation — without a depot-to-last-mile-carrier handoff that breaks the chain. Cargo moves from Logan directly into Eagle’s Chelsea facility and then directly into Eagle’s owned delivery vehicles. The compliance framework doesn’t transfer between parties at either transition.
Because Eagle is the operator — not a coordinator managing sub-contractors — exception response is direct. A temperature deviation, a delivery window change, or a same-day re-supply need is handled by the party already in the chain with knowledge of the shipment’s compliance history and temperature profile. Eagle’s Logan proximity makes same-day rescue repack and next-flight-out coordination executable, not aspirational. The response capability is structural, not a service tier upgrade.
Eagle manages pharmaceutical last mile delivery from Logan to final receipt under a single GDP-documented chain of custody — owned vehicles, white-glove drivers, no sub-handoffs.
Contact Eagle Life Science to discuss what owned last-mile delivery means for your cold chain program.
https://www.eagle-freight.com/wp-content/uploads/2026/06/Laboratory-Sample-Logistics-in-Boston-The-Chain-of-Custody-Gap-Most-Organizations-Miss-at-Logan.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2026-06-16 10:27:042026-06-16 10:28:35Laboratory Sample Logistics in Boston: The Chain-of-Custody Gap Most Organizations Miss at Logan https://www.eagle-freight.com/wp-content/uploads/2026/06/The-process-of-loading-medical-ampoules-for-vaccines-onto-a-conveyor_.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2026-06-16 08:35:242026-06-16 08:35:26Why CDMOs Are Debating Freight Mode When Pharmaceutical Importer of Record Liability Is the Real Risk https://www.eagle-freight.com/wp-content/uploads/2026/02/Dry-Ice-Replenishment-In-Bond.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2026-02-27 15:46:322026-04-24 11:12:49How Dry Ice Shipping in Bond Protects Pharmaceutical Shipments https://www.eagle-freight.com/wp-content/uploads/2025/12/How-Cold-Chain-Logistics-Ensures-Pharmaceutical-Safety.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2025-12-22 10:01:342026-04-24 16:56:17How Cold Chain Pharmaceutical Logistics Ensures Product Integrity & Patient Safety https://www.eagle-freight.com/wp-content/uploads/2025/12/How-Cold-Chain-Logistics-Safeguards-Pharmaceutical-Integrity.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2025-12-18 12:29:442026-04-24 11:12:50How to Evaluate a Cold Chain Logistics Provider for Pharmaceutical Shipments
Laboratory Sample Logistics in Boston: The Chain-of-Custody Gap Most Organizations...